Despite being the wealthiest nation on the face of the planet, the United States . Kidneys are , followed by livers. While the liver is the only human organ known capable of regenerating itself, if you damage yours badly enough for long enough — as some 30 million Americans have — then the only treatment is a transplant. Assuming for doctors to stick in you. Every year demand for replacement livers outstrips supply by a scope of tens of thousands.
“Only one-third of those on the liver transplant waiting list will be transplanted, and the demand for livers is projected to increase 23 percent in the next 20 years,” a multidisciplinary team of researchers observed in 2016’s . “Exacerbating the organ shortage problem, the donor pool is expected to shrink further because of the obesity epidemic. Liver steatosis [aka ] is increasingly common in donors and is a significant risk factor in liver transplantation.”
To address this critical shortage, the study authors note that doctors have explored a variety of cutting-edge regimens, from cell repopulation and tissue engineering, nanoparticles to genomics, mechanical aids to porcine-derived xenotransplantation, all with varying degrees of success. Cellular repopulation has been used for years, a process that injects healthy liver cells into the patient’s damaged organ through a portal vein where they adhere themselves to the existing cellular scaffolding and grow into new, functional liver tissue.
“Creating an immediately available and inexhaustible supply of functioning liver cells from autologous tissue would allow early intervention in patients with hepatic failure and would allow liver cells to be infused over a longer period of time,” the 2016 study’s authors note. “Combined with recent advances in genome-editing technology, such liver cells could be used widely to treat devastating liver-based inborn errors of metabolism and to eliminate the need for a life-long regimen of immunosuppressive drugs and their complications.” The downside to this technique is the pace at which the donor cells proliferate, making it a poor tool against acute liver failure.
Extracellular Vesicle-based therapies, on the other hand, leverage the body’s intracellular communications pathways to deliver drugs with, “high bioavailability, exceptional biocompatibility, and low immunogenicity,” according to 2020’s . “They provide a means for intercellular communication and the transmission of bioactive compounds to targeted tissues, cells, and organs” including “fibroblasts, neuronal cells, macrophages, and even cancer cells.”
EVs are the postal letters that cells send one another. They come in a variety of sizes from 30 to 1000 nm and have exterior membranes studded with multiple adhesive proteins that grant them entry into any number of different types of cells. Exploiting the biological equivalent to a janitor’s key ring, researchers have begun tucking therapeutic nanoparticles into EVs and using them to discreetly inject treatments into the targeted cells. However, these treatments are still in the experimental stages and are most effective against acute liver failure and inborn metabolic diseases rather than end-stage liver failure.
Mechanical aids, the hepatocytic equivalent to a dialysis machine, like the (SRBAL, above) are ideal for treating cases of acute liver failure, able to take over the entirety of the patient’s liver function externally and immediately. However, such procedures are both expensive and temporary. The SRBAL can only support a patient for up to two weeks, making it more suitable for keeping someone alive until a donor can be located rather than as a permanent, pacemaker-like solution.
The has also shown promise, though they too are still in early development and largely not near ready for widespread adoption. Interspecies transplantation using genetically-engineered pig organs are , with surgeons this past January (though he died of complications two months later). Pig and have similarly been transplanted into human recipients, often with less drastic side effects than death.
No matter where the transplanted organ comes from, getting it into the patient is invariably going to involve a significant surgical procedure. However, the recently unveiled its non-invasive solution: tricking the patient’s body into growing a series of miniature, ectopic liver “organoids” in its own like a crop of blood-scrubbing potatoes.
For those of you who dozed through high school bio, a quick recap of terms. The lymphatic system is a part of the immune system that serves to circulate some 20 liters of throughout your body, absorb excess back into the bloodstream, and incubate critical lymphocytes like . Organoids, on the other hand, are that , but do so ectopically, in that they function in a different part of the body as a regular liver. Blood-scrubbing potatoes are self-explanatory.
“Fundamentally, Lygenesis uses the lymph node, your body’s natural bio reactors typically used for T-cells,” company CEO and co-founder Michael Hufford, told Engadget. “We hijacked that same biology, we engraft our therapies into the lymph nodes to grow functioning ectopic organs.”
“We use an outpatient endoscopic ultrasound procedure where we’re going down through the mouth of the patient using standard endoscopic equipment,” Hufford continued. “We engraft ourselves there in minutes under light sedation, so it’s very low medical risk and also is really quite inexpensive.” He notes that the average cost for a proper, in-hospital liver transplant will set you back around a million dollars. Lygenesis’ outpatient procedure “is billed at a couple of thousand or so,” he said.
More importantly, the Lygenesis technique doesn’t require a full donated liver, or even a large fraction of one. In fact, each donated organ can be split among several dozen recipients. “Using our technology a single donated liver can reach 75 or more patients,” Hofford said. The process of converting a single donated liver into all those engraftable samples takes a team of three technicians more than six hours and 70 steps to complete. The process does not involve any gene manipulation, such as CRISPR editing.
This process is quite necessary as patients cannot donate culturable liver cells to themselves. “Once you have end-stage liver disease, you typically have a very ,” Hofford noted. “It will bleed at the slightest sort of intervention.” Even the simple act of collecting cellular samples can quickly turn deadly if the wrong bit of organ is bisected.
And it’s not only the transplant recipients themselves who are unable to donate. Hofford estimates between 30 and 40 percent of donated livers are too worn to be successfully transplanted. “One of the benefits of our technology is we’re using organs that have been donated but will otherwise be discarded,” he said.
Once engrafted into a lymph node, the liver organoid will grow and vascularize over the course of two to three months, until it is large enough to begin supporting the existing liver. Hufford points out that even with end-stage disease, a liver can retain up to 30 percent of its original functionality, so these organoids are designed to augment and support the existing organ rather than replace it outright.
Lygenesis is currently in Phase 2A of the , meaning that a small group of four patients have each received a single engraftment in a lymph node located in their central body cavity near the liver itself (the body has more than 500 lymph nodes and apparently this treatment can technically target any of them). Should this initial test prove successful subsequent study groups will receive increasing numbers of engraftment, up to a half dozen, to help the company and federal regulators figure out the optimal number of organoids to treat the disease.
While the liver’s inherent regenerative capabilities make it an ideal candidate for this procedure, the company is also developing similar treatments for the kidneys, pancreas and thymus gland as well as inborn metabolic liver ailments like . These efforts are all at much earlier points in development than the company’s end stage liver work. “Within the next five years, we would love to see our liver program submitted to the FDA as a new biologic therapy and be commercially available,” Hufford said. “I think that’d be a realistic timeframe.”
All products recommended by Engadget are selected by our editorial team, independent of our parent company. Some of our stories include affiliate links. If you buy something through one of these links, we may earn an affiliate commission. All prices are correct at the time of publishing.File source